Testing a new medication to reduce pain crises in sickle cell disease

This trial studied crizanlizumab, a medication given intravenously, to understand how it moves through the body and how it affects sickle cell disease. Researchers followed participants for up to five years to examine whether this treatment was safe and whether it reduced the frequency of vaso-occlusive crises—the painful episodes that people with sickle cell disease experience. The medication was tested at two different doses to see which worked best.

Sickle cell disease causes severe, unpredictable pain crises that can be life-altering for patients. This trial investigated whether this new medication could prevent or reduce these painful episodes by targeting a specific mechanism involved in the disease.